We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sourcebio International Plc | LSE:SBI | London | Ordinary Share | GB00BKSB1674 | ORD GBP0.0015 |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
105.00 | 150.00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
- |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
- | O | 0 | 115.00 | GBX |
Sourcebio (SBI) Share Charts1 Year Sourcebio Chart |
|
1 Month Sourcebio Chart |
Intraday Sourcebio Chart |
Date | Time | Title | Posts |
---|---|---|---|
18/10/2024 | 07:01 | SOURCE BIO INTERNATIONAL | 589 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
Top Posts |
---|
Posted at 18/7/2024 13:07 by jimbren I would have preferred to take part in the buyback if a capital reduction as my in price was 111, so little or no capital gain, Vs hefty potential tax on the dividend income. |
Posted at 18/7/2024 13:06 by jimbren Companies House has nothing useful. Just a clarification of the numbers in the mysterious share buyback.l - and a detailed new Articles of Association that I can't really interpret.I wondered if someone here had re-materialised into certificates and thus got more information or even an offer to take part in the buyback (as would only be fair). I have asked my broker if they received any more info than we can see on the website or at Companies House (and whether I should re-materialise). |
Posted at 18/7/2024 10:48 by jimbren Weird lack of comms. Divi paid in 23-24 tax year. Into my Dealing Account. So tax now due. Better to have than not have, of course.But if share buyback at 115 was inclusive of dividend then presumably price of share is now 115-28=87p. This theory evidenced by A J Bell telling me that the ex-date was 8th March 2024. If we had some accounts for year to December 2023 might help! Should I re-materialize my shares, out of AJ Bell so I can directly get all company notices rather than via my proxy who may not send everything on (ie AJ Bell)? Views? |
Posted at 29/12/2022 11:21 by supernumerary finkie - don't be so lazy!'As previously announced on 23 November 2022, following the approval of the proposed Cancellation by Shareholders at the General Meeting held today, the last day of dealings in the Company's Ordinary Shares on AIM will be 29 December 2022 and the Cancellation will become effective at 7:00 a.m. on 30 December 2022, subject to a Dealing Notice, as defined in the AIM Rules for Companies, being issued. The Re-Registration of the Company as a private company is expected to take place on or around 18 January 2023.' yes yes; but 'at a lower price' makes no sense 9degrees - yes, farewell indeed. Been in and out here in the past, and was contemplating buying a chunk again, but saved by the bell. I suspect, however, they'll be back in some form or other... |
Posted at 29/12/2022 10:09 by 9degrees Good bye SBI I feel i have been ripped off whatever their good intentions |
Posted at 17/12/2022 21:55 by finkie And a further question what happens to investors buying stock and holding at 100p do they still own a part of source bio as a private company but able to own at a lower price? |
Posted at 09/12/2022 14:23 by assword Just sold for 110 and moved on. Take the hit and learn a lesson or two. Thought best strike now with what little I got out of SBI to move for a stock awaiting results before end of Q4. At least I had the money to trade with now, rather than later. Hopefully it's a double bagger and I get back what I lost out on !!! |
Posted at 09/11/2022 08:11 by brummy_git Planned 115p/share tender offer for SourceBio shareholders, before going private.All the news here www.linkedin.com/pos |
Posted at 08/9/2022 06:28 by samewe Let’s hope we will see some upwards movement on the share price to above 200p. |
Posted at 05/4/2022 15:13 by james188 base7 - They paid for LDPath in cash because the share price is(and was)so low that it made no sense to pay in shares (even if the vendors had wanted to do that). Contrast that to the EKF acquisition of a US lab which was done when the EKF share price was pretty much double what it is now. That might also have been noticed.I think that the market reaction today has been relatively cautious because there will have to be a huge increase in the core business revenues - and healthcare diagnostics in particular - to replace the large hole left by the drop in revenues from infectious diseases testing. It was alway known that that was going to happen, but it is still a challenge. In my view, the management team deserves a lot of credit for spotting the COVID business opportunity and then executing it so well. They now need to repeat the trick and demonstrate that the price paid for LDPath was reasonable. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions